Safety of Pregnancy in BRCA Mutated Breast Cancer Patients

NCT ID: NCT03673306

Last Updated: 2024-12-13

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

4732 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-01-16

Study Completion Date

2023-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The present study aims at refining the understanding of the effect of pregnancy on breast cancer outcomes in the specific population of BRCA mutated patients with known history of breast cancer.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Breast cancer BRCA Young Survivorship

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pregnant cohort

Women with one or more pregnancies any time after breast cancer diagnosis

Clinical outcomes

Intervention Type OTHER

Clinical outcomes

Non-pregnant cohort

Women with no subsequent pregnancies after breast cancer diagnosis

Clinical outcomes

Intervention Type OTHER

Clinical outcomes

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Clinical outcomes

Clinical outcomes

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of invasive breast cancer between January 2000 and December 2020;
* Breast cancer diagnosis at the age of ≤ 40 years;
* Known presence of germline BRCA mutation.

Exclusion Criteria

* Known BRCA mutation with no diagnosis of invasive breast cancer;
* Diagnosis of ovarian cancer or other malignancies with no history of invasive breast cancer;
* Diagnosis of hereditary or familiar invasive breast cancer without BRCA mutation or with BRCA genes not tested;
* Diagnosis of invasive breast cancer with germline BRCA variants of unknown significance.
Minimum Eligible Age

18 Years

Maximum Eligible Age

40 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Jules Bordet Institute

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Yale University

New Haven, Connecticut, United States

Site Status

Dana-Farber Cancer Institute

Boston, Massachusetts, United States

Site Status

Michigan State University

Lansing, Michigan, United States

Site Status

Mayo Clinic

Rochester, Minnesota, United States

Site Status

University of North Carolina - Lineberger Comprehensive Cancer Center

Chapel Hill, North Carolina, United States

Site Status

Cleveland Clinic Taussig Cancer Institute

Cleveland, Ohio, United States

Site Status

Lifespan Cancer Institute

Providence, Rhode Island, United States

Site Status

Hospital Aleman

Buenos Aires, , Argentina

Site Status

Hospital Italiano de Buenos Aires

Buenos Aires, , Argentina

Site Status

Instituto Alexander Fleming

Buenos Aires, , Argentina

Site Status

kConFab, Follow-up Project

Melbourne, Victoria, Australia

Site Status

Peter MacCallum Cancer Centre

Melbourne, Victoria, Australia

Site Status

Medical University of Vienna

Vienna, , Austria

Site Status

Cliniques Universitaires Saint-Luc UCL

Brussels, , Belgium

Site Status

Institut Jules Bordet

Brussels, , Belgium

Site Status

University Hospitals Leuven, KU Leuven

Leuven, , Belgium

Site Status

Clinical Center University of Sarajevo

Sarajevo, , Bosnia and Herzegovina

Site Status

Hospital Sírio-Libanês

Brasília, , Brazil

Site Status

Cancer Institute ICESP

São Paulo, , Brazil

Site Status

Mc Gill University

Montreal, , Canada

Site Status

Bergonie Institute

Bordeaux, , France

Site Status

Leon Berard Cancer Center

Lyon, , France

Site Status

Hopital Saint Louis

Paris, , France

Site Status

Institut Curie

Paris, , France

Site Status

Centre Henri Becquerel

Rouen, , France

Site Status

Institut Gustave Roussy

Villejuif, , France

Site Status

Todua Clinic

Tbilisi, , Georgia

Site Status

Universitätsklinikum Hamburg-Eppendorf

Hamburg, , Germany

Site Status

Leitung, Brustzentrum der Universität München (LMU)

München, , Germany

Site Status

Tata Memorial Centre

Mumbai, , India

Site Status

Sharett Institute of Oncology - Hadassah Hebrew University Medical Center

Jerusalem, , Israel

Site Status

Davidoff Cancer Center - Rabin Medical Center - Beilinson

Petah Tikva, , Israel

Site Status

Sheba Medical Center

Tel Aviv, , Israel

Site Status

Tel Aviv Sourasky Medical Center

Tel Aviv, , Israel

Site Status

Università Politecnica delle Marche - Azienda Ospedaliero-Universitaria Ospedali Riuniti Umberto I - GM Lancisi - G Salesi

Ancona, , Italy

Site Status

Oncological Center CRO

Aviano, , Italy

Site Status

Azienda Ospedaliera "Papa Giovanni XXIII"

Bergamo, , Italy

Site Status

Azienda Ospedaliero Universitaria di Cagliari

Cagliari, , Italy

Site Status

Candiolo Cancer Center (IRCCS)

Candiolo, , Italy

Site Status

Florence University Hospital - University of Florence

Florence, , Italy

Site Status

IRCCS Ospedale Policlinico San Martino

Genova, , Italy

Site Status

Azienda USL Toscana Sud Est - Misericordia Hospital

Grosseto, , Italy

Site Status

IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori

Meldola, , Italy

Site Status

European Institute of Oncology

Milan, , Italy

Site Status

Fondazione IRCCS Istituto Nazionale dei Tumori

Milan, , Italy

Site Status

IRCCS Ospedale San Raffaele

Milan, , Italy

Site Status

Azienda Ospedaliero-Universitaria Policlinico, University of Modena and Reggio Emilia

Modena, , Italy

Site Status

San Gerardo Hospital ASST Monza

Monza, , Italy

Site Status

University of Naples "Federico II"

Naples, , Italy

Site Status

IOV (Istituto Oncologico Veneto)

Padua, , Italy

Site Status

IRCCS Policlinico San Matteo

Pavia, , Italy

Site Status

Azienda Ospedaliero Universitaria Pisana - Ospedale Santa Chiara

Pisa, , Italy

Site Status

Nuovo Ospedale di Prato - Santo Stefano

Prato, , Italy

Site Status

AOU Policlinico Umberto I

Roma, , Italy

Site Status

ASL Roma 1 - Centro Oncologico S. Spirito - Nuovo Regina Margherita

Rome, , Italy

Site Status

Policlinico Universitario Agostino Gemelli IRCCS

Rome, , Italy

Site Status

Saint Joseph University of Beirut

Beirut, , Lebanon

Site Status

Instituto Nacional de Cancerologia

Mexico City, , Mexico

Site Status

Hospital Zambrano Hellion - Tecnologico de Monterrey

Monterrey, , Mexico

Site Status

Netherlands Cancer Institute

Amsterdam, , Netherlands

Site Status

Medical University of Gdansk

Gdansk, , Poland

Site Status

Poznan University of Medical Sciences, University Hospital of H. Swiecicki

Poznan, , Poland

Site Status

Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology

Warsaw, , Poland

Site Status

Military institute of Medicine

Warsaw, , Poland

Site Status

Champalimaud Foundation

Lisbon, , Portugal

Site Status

Hospital de Santa Maria and Instituto de Medicina Molecular of the Faculty of Medicine of the University of Lisbon

Lisbon, , Portugal

Site Status

Institute of Oncology "Ion Chiricuta"

Cluj-Napoca, , Romania

Site Status

Institute for Oncology and Radiology of Serbia

Belgrade, , Serbia

Site Status

Oncology Institute of Vojvodina - University of Novi Sad

Novi Sad, , Serbia

Site Status

St. Elisabeth Cancer Institute (Onkologicky ustav sv. Alzbety-OUSA)

Bratislava, , Slovakia

Site Status

University of Ulsan, College of Medicine, Asan medical center

Seoul, , South Korea

Site Status

Hospital Clínic of Barcelona

Barcelona, , Spain

Site Status

Vall D'Hebron University Hospital

Barcelona, , Spain

Site Status

Hospital Universitario 12 de Octubre

Madrid, , Spain

Site Status

Ramon y Cajal - IOB Institute of Oncology (Madrid) - International Breast Cancer Center (IBCC)

Madrid, , Spain

Site Status

Hospital Universitari Son Espases Palma

Palma de Mallorca, , Spain

Site Status

INCLIVA, University Hospital of Valencia

Valencia, , Spain

Site Status

Capio Saint Göran's Hospital

Stockholm, , Sweden

Site Status

Karolinska University Hospital

Stockholm, , Sweden

Site Status

Stockholm Southern Hospital (Södersjukhuset)

Stockholm, , Sweden

Site Status

Oncology Institute of Southern Switzerland

Lugano, , Switzerland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Argentina Australia Austria Belgium Bosnia and Herzegovina Brazil Canada France Georgia Germany India Israel Italy Lebanon Mexico Netherlands Poland Portugal Romania Serbia Slovakia South Korea Spain Sweden Switzerland

References

Explore related publications, articles, or registry entries linked to this study.

Lambertini M, Ameye L, Hamy AS, Zingarello A, Poorvu PD, Carrasco E, Grinshpun A, Han S, Rousset-Jablonski C, Ferrari A, Paluch-Shimon S, Cortesi L, Senechal C, Miolo G, Pogoda K, Perez-Fidalgo JA, De Marchis L, Ponzone R, Livraghi L, Estevez-Diz MDP, Villarreal-Garza C, Dieci MV, Clatot F, Berliere M, Graffeo R, Teixeira L, Cordoba O, Sonnenblick A, Luna Pais H, Ignatiadis M, Paesmans M, Partridge AH, Caron O, Saule C, Del Mastro L, Peccatori FA, Azim HA Jr. Pregnancy After Breast Cancer in Patients With Germline BRCA Mutations. J Clin Oncol. 2020 Sep 10;38(26):3012-3023. doi: 10.1200/JCO.19.02399. Epub 2020 Jul 16.

Reference Type RESULT
PMID: 32673153 (View on PubMed)

Lambertini M, Blondeaux E, Agostinetto E, Hamy AS, Kim HJ, Di Meglio A, Bernstein Molho R, Hilbers F, Pogoda K, Carrasco E, Punie K, Bajpai J, Ignatiadis M, Moore HCF, Phillips KA, Toss A, Rousset-Jablonski C, Peccatori FA, Renaud T, Ferrari A, Paluch-Shimon S, Fruscio R, Cui W, Wong SM, Vernieri C, Ruddy KJ, Dieci MV, Matikas A, Rozenblit M, Villarreal-Garza C, De Marchis L, Del Mastro L, Puglisi F, Del Pilar Estevez-Diz M, Rodriguez-Wallberg KA, Mrinakova B, Meister S, Livraghi L, Clatot F, Yerushalmi R, De Angelis C, Sanchez-Bayona R, Meattini I, Cichowska-Cwalinska N, Berliere M, Salama M, De Giorgi U, Sonnenblick A, Chiodi C, Lee YJ, Maria C, Azim HA Jr, Boni L, Partridge AH; BRCA BCY Collaboration. Pregnancy After Breast Cancer in Young BRCA Carriers: An International Hospital-Based Cohort Study. JAMA. 2024 Jan 2;331(1):49-59. doi: 10.1001/jama.2023.25463.

Reference Type RESULT
PMID: 38059899 (View on PubMed)

Blondeaux E, Sonnenblick A, Agostinetto E, Bas R, Kim HJ, Franzoi MA, Bernstein-Molho R, Linn S, Kwong A, Pogoda K, Balmana J, Smeets A, Bajpai J, Moore HCF, Partridge AH, Phillips KA, Toss A, Rousset-Jablonski C, Peccatori FA, Renaud T, Ferrari A, Paluch-Shimon S, Mando P, Lee JE, Fruscio R, Cui W, Wong SM, Vernieri C, Ruddy KJ, Dieci MV, Matikas A, Rozenblit M, Guven DC, Lee M, Villarreal-Garza C, Hwang SE, De Marchis L, Puglisi F, Kemp Z, Meireles PA, Parokonnaya A, Werutsky G, Okano M, Azim HA Jr, Mati K, Rosenberg S, Gelber R, Boni L, Lambertini M. Association between risk-reducing surgeries and survival in young BRCA carriers with breast cancer: an international cohort study. Lancet Oncol. 2025 Jun;26(6):759-770. doi: 10.1016/S1470-2045(25)00152-4. Epub 2025 May 8.

Reference Type DERIVED
PMID: 40347973 (View on PubMed)

Lambertini M, Blondeaux E, Tomasello LM, Agostinetto E, Hamy AS, Kim HJ, Franzoi MA, Bernstein-Molho R, Hilbers F, Pogoda K, Wildiers H, Bajpai J, Ignatiadis M, Moore HCF, Partridge AH, Phillips KA, Toss A, Rousset-Jablonski C, Criscitiello C, Renaud T, Ferrari A, Paluch-Shimon S, Fruscio R, Cui W, Wong SM, Vernieri C, Ruddy KJ, Dieci MV, Matikas A, Rozenblit M, Villarreal-Garza C, De Marchis L, Puglisi F, Rodriguez-Wallberg KA, Duhoux FP, Livraghi L, Bruzzone M, Boni L, Balmana J. Clinical Behavior of Breast Cancer in Young BRCA Carriers and Prediagnostic Awareness of Germline BRCA Status. J Clin Oncol. 2025 May 10;43(14):1706-1719. doi: 10.1200/JCO-24-01334. Epub 2025 Feb 24.

Reference Type DERIVED
PMID: 39993249 (View on PubMed)

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IJB-BRCAPreg-CE2630

Identifier Type: -

Identifier Source: org_study_id